SUMNIARY
The effect of levodopa on the exterinally recorded preejection period (PEP), blood pressure, and heart rate was evaltuated in patienits with Parkinson's disease during the fir-st 2 weeks of therapy and after 3 this area was noted so that it could be userl foi subsequent determinationls. The nilciroplhoiae fora the plhon'ocardiogram xxwas placed wherue the second heart sounds xwere most clearlv definied. The measuremnents included (1) the inter val froma the onset of the QRS complex of the electrocar diogram to the peak of the first major vxibrationi of the second heart sound (Q-S., interxval), the latter end poinlt xvas utilized rathei thain the beginniing of the second soun-d becacuse it xxwas coisisteil]-xxell defiined and is less subject to baseliine variation and background interference, (2 th-ie initerval froIn the beginning uipstroke ot the carotid pulse conitoir to the tiough of the ilncisUna (left ventricular ejection time, LVET) and t3) the R-R interval, xvhich xwas uised to deteri'ne heart rate (heart rate = 120/R-R interval) Ten consecutive heart beats xvere measured and taken as the mean onlv xvheii the previously described end points were xvell defined. The PEP xx as determined bh subtracting the LVET from the Q-S., interxvals. The LVET Wlas corrected for heart rate bv the folloxving: LVET 6 houris iunitil the patienit couild tolerate a dose of 1.0 g xvithi nlo side effects. At this poinlt, the initial sttidies wvere carried out in a number of patienits. The dose was theni gradually iiicreased durinig the niext 7 to 10 dax.s. Tlihis, the daily dose of lex odopa obtainied onl the dav before the cardiovascular studv rianiged from 1.5 to 4.5 g. PEP, blood pressure, aiid heart rate xe e deterimiined before aiid at 30, 60, 90, anid 120 mim folloxxinig placebo, 1.0 aind 1.5 g of levodopa adminiister-ed orally on1 successive davs. In some patienits, the effect of 0.5 g xxvas also recorded. In six of the patieints, the effects of 1.5 g of lexvodopa xxwere sttuldied againl on the folloxvinig day 45 mi after oral adminiistrationi of propr-anlolol (10 mg The effects of a placebo resembling the levodopa capsule on the average PEP of six patients is shoxsxn in figure 2. During the 2-lhour period of observation, PEP xvas shortenedl by 2 msec in one patient, but was either uinchanged or prolonged in the other five. The avxerage values following the placebo wN1ere more prolonged than the recordings obtained l)efore administration. This prolongation, however, x cas statisticallv significant (P < 0.05) only at the 90-min recording. Blood pressure and heart rate wvere not statistically charnged.
Effects of Levodopa on PEP, Blood Pressure, and Heart Rate during the First 2 Weeks of Therapy PEP Xvas not significantly7 altered after administration of 0.5 g of lex odopa to fotur patiecnts. Accordingly?, all sul)sequent studies xerc carried out with either 1.0 or 1.5 g of the drug.
The effects of 1.0 and 1.5 g of levodopa on PEP x ere determined in eight and niie patienits, respectiv-ely (se ven patients receixved both doses). PEP x as imaximallv shortened :30 to 60 min after administration of both doses. Levodopa did not significantly affect the heart rate or blood pressure, either before or after propranolol (table 2) . However, the control systolic and diastolic blood pressures were significantly higher (P <0.05) and the heart rate was significantly lower (P < 0.05) after propranolol. The control PEP, however, was not significantly altered by propranolol. This last finding is consistent with previous observations.6
Effect of Levodopa on PEP during the Initial 2 Weeks of Therapy and after 3 Months of Continuous Administration
The effects of levodopa ( 1.5 g) on PEP were determined in six patients during the first 2 weeks of therapy, and again after the drug was administered for 3 months. Comparison of the results is shown in figure 4 . During the initial 2 weeks of therapy, the PEP was maximally reduced at the 30- Figure 4 spectively (P < 0.001 ). Heart rate was sigosec) in six patients during the control period nificantly slower after chronic administration 60, 90, and 120 min following levodopa (1.5 g). Infusions of epinephrine at 0.01, 0.02, and 0.04 gg/kg/min resulted in significant shortening of the PEP in a dose-related fashion before and after administration of levodopa. Shortening of the PEP during adminiistration of epinephrine has previously been reported.4 6 8 Statistical comparison of the changes before and after levodopa indicated that the changes were not significantly different except for those obtained after the infusioni of 0.01 jug/kg/mil. With this infusioni rate of epinephrine, the PEP wx as reduced by 6.7 + 0.5 Insec before levodopa and 4.5 + 0.7 msec after levodopa (P < 0.05).
The only significant blood pressure change which occurred wvith infusion of the amines was with the 0.04-,g/kg/min infusion of ,ug/kg/min of epinephrine, heart rate was increased an average of 5 beats/min both before and after levodopa therapy.
Side Effects
Three patients who participated in the initial phase of this study were not investigated the second time because levodopa had to be discontinued because of adverse effects. Two of these patients experienced nausea and vomiting to a greater degree than the antiparkinsonian effect, and the third developed symptomatic orthostatic hypotension and acute myocardial infarction from which he had an uneventful recovery. Other side effects did not require discontinuation of the drug. Four patients developed dyskinesia; three experienced akathisia, and one noted intermittent torsion dystonia of the neck, puckering of the lips, and abdominal muscle contractions. One patient who had been totally bed-fast prior to levodopa therapy experienced symptomatic orthostatic hypotension and intermittent episodes of hypertension and flushing which lasted for approximately 1 hour.
Discussion
This study has demonstrated that oral administration of levodopa (1.0 and 1.5 g) significantly shortens the PEP in patients with Parkinson's disease during the first 2 weeks of therapy. Thus, it appears that sufficient amounts of a cardioactive cathecholamine are generated to increase myocardial contractility. This conclusion is supported by the following data: (1) Shortening of PEP was observed in the absence of significant change in blood pressure. Previous studies have shown that such a change correlates well with other methods of detecting a positive inotropic effect.9-12 (2) Other drugs with positive inotropic effects shorten the PEP.4 6, 13 (3) The administration of the beta-adrenergic blocking agent, propranolol. completely prevented the shortening of the PEP by levodopa.
This study does not indicate wxhich of the products of levodopa metabolism, dopamine or norepinephrine, was responsible for the increase in myocardial contractility. Howvever, measurements of renal plasma flow in patients with Parkinson's disease treated with the same dose of levodopa indicated that renal vascular resistance significantly decreases.'4 Such an effect is characteristic of the action of dopamine15' 16 and does not appear with norepineprhine, which increases renal resistance.'7 Furthermore, dopamine, unlike other sympathomimetic amines, may increase myocardial contractility to a greater degree than it increases heart rate.'8 The response to lexvodopa in our study followed this pattern. Thus, dopamine appears to be the major cardioactive catecholamine produced by decarboxylation of levodopa. However, dopamine stimulates the myocardium both by a direct action of beta-adrenergic receptors and indirectly by releasing norepinephrine from sympathetic stores. '19 20 Thus, released norepinephrine may have contributed to the positive inotropic effect.
The action of dopamine on the myocardium may have both beneficial and detrimental consequences. The positive inotropic effect could be helpful to patients wvith congestive heart failure, and, in fact, levodopa has been shown to produce a positive inotropic effect and an increase in sodium excretion in such patients.'4 On the negative side, drugs with a positive inotropic action increase myocardial oxygen requirements, and this could produce coronary insufficiency in a patient with limited coronary reserve. Action on beta-adrenergic receptors also increases ectopic activity, especially in the presence of sensitizing agents such as cyclopropane and halothane,2' or in the ischemic heart. The development of disturbances in cardiac rhythm have been reported in the treatment of Parkinson's disease with levodopa.2-'2 In addition, drugs acting on beta-adrenergic receptors increase Circulation, Volume XLV. January 197) transmission through the atriox-entricular node, and patients xxvith atrial fibrillation could have a rapid increase in ventricular rate.
The results of this study suggest se evral means by xxhich potentially detrimenital effeets can be minimized. First, since shortening of PEP xwas blocked by relatixvely smiiall doses of propranolol, this drug could be used to prevent cardiac stimulation and, in fact, lhas been beneficial in treating cardiac arrhythmias produced by levodopa.25 Propranolol has also been used to treat the orthostatic hypotension produced by levodopa. In that report, the use of propranolol did not appear to reduice the efficacy of levodopa in the therapy of Parkinson's disease. In this regclard, it xvas interesting to note that the blood pressure of our patients recorded in the supine position xvas higher after administration of propranolol. Secondly, there appears to be tolerance to the positive inotropic effect of levodopa after 3 months of continuous therapy. Therefore, it is possible that undesirable cardiac stiml-ulation could be prevented by building the dose up gradually over a prolonged period, as suggested by Cotzias and associates.--WVe did not discoxver the mechanism responsible for the failure of lex odopa to shorten the PEP after continued therapy. Since dopamine and epinephrine produced similar shortening of PEP before and after continuous therapy xvith levodopa, beta-adrenergic blockade cannot be the responsible mechanism. Since gastrointestinal absorption of lex odopa is not affected by prolonged administration of the drug, '27 
